首页> 外文期刊>Internal medicine. >Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity
【24h】

Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity

机译:利拉鲁肽是调节下丘脑肥大和肥胖的糖尿病患者食欲的潜在有用药物

获取原文
获取原文并翻译 | 示例
           

摘要

Hypothalamic hyperphagia and obesity are characterized by a lack of satiety and an abnormally high appetite that is difficult to control. We herein report the cases of two patients with hypothalamic hyperphagia and obesity with MRI-detectable hypothalamic lesions. These patients suffered from diabetes mellitus associated with an abnormal eating behavior and weight gain. Liraglutide was successfully used to treat their diabetes mellitus and suppress their abnormal appetites. Glucagon-like peptide-1 analogues, including liraglutide, are promising treatment options in patients with hypothalamic hyperphagia and obesity, as these agents enhance the hypothalamic input of the satiety signal, which is lacking in such patients.
机译:下丘脑肥大和肥胖的特征是缺乏饱腹感和食欲异常异常,难以控制。我们在此报告了两名具有MRI可检测到的下丘脑病变的下丘脑吞咽过多和肥胖症患者的病例。这些患者患有与异常饮食行为和体重增加有关的糖尿病。利拉鲁肽已成功用于治疗糖尿病和抑制食欲异常。胰高血糖素样肽-1类似物(包括利拉鲁肽)是下丘脑食管过多和肥胖症患者的有前途的治疗选择,因为这些药物可增强下丘脑对饱食感信号的输入,而这类患者缺乏这种信号。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号